The Company reports results of a double-blinded, randomized, placebo-controlled study, known as “MissionEB,” investigating CORDStrom for treatment of RDEB in pediatric patients, which evidence a ...
NEWTOWN, Pa., June 03, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to ...
Eloxx Pharmaceuticals Announces Submission of Investigational New Drug (IND) Application for ZKN-013
ZKN-013 in development for treatment of recessive dystrophic epidermolysis bullosa (RDEB) and junctional epidermolysis bullosa (JEB) Additional IND filing for ZKN-013 for treatment of familial ...
INmune Bio, Inc. announced positive results from a double-blinded, randomized clinical trial named "MissionEB" for its product CORDStrom, aimed at treating Recessive Dystrophic Epidermolysis Bullosa ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results